424B3

Filed Pursuant to Rule 424(b)(3)
File Number 333-119428

PROSPECTUS SUPPLEMENT NO. 10

Prospectus Supplement dated September 8, 2005
to Prospectus declared
effective on November 23, 2004
(Registration No. 333-119428)
as supplemented by that Prospectus Supplement No. 1 dated November 23, 2004,
that Prospectus Supplement No. 2 dated December 21, 2004,
that Prospectus Supplement No. 3 dated January 3, 2005,
that Prospectus Supplement No. 4 dated January 14, 2005,
that Prospectus Supplement No. 5 dated February 11, 2005,
that Prospectus Supplement No. 6 dated February 14, 2005,
that Prospectus Supplement No. 7 dated March 2, 2005,
that Prospectus Supplement No. 8 dated April 6, 2005, and
that Prospectus Supplement No. 9 dated May 16, 2005

ALLIANCE PHARMACEUTICAL CORP.

This Prospectus Supplement No. 10 supplements our Prospectus dated November 23, 2004 and the Prospectus Supplement No. 1 dated November 23, 2004, Prospectus Supplement No. 2 dated December 21, 2004, Prospectus Supplement No. 3 dated January 3, 2005, Prospectus Supplement No. 4 dated January 14, 2005, Prospectus Supplement No. 5 dated February 11, 2005, Prospectus Supplement No. 6 dated February 14, 2005, Prospectus Supplement No. 7 dated March 2, 2005, Prospectus Supplement No. 8 dated April 6, 2005 and Prospectus Supplement No. 9 dated May 16, 2005.

The shares that are the subject of the Prospectus have been registered to permit their resale to the public by the selling stockholders named in the Prospectus. We are not selling any shares of common stock in this offering and therefore will not receive any proceeds from this offering. You should read this Prospectus Supplement No. 10 together with the Prospectus and each prior Prospectus Supplement referenced above.

This Prospectus Supplement includes the attached Current Report on Form 8-K of Alliance Pharmaceutical Corp. filed on September 8, 2005 with the Securities and Exchange Commission.

Our common stock is traded on the Over-the-Counter Bulletin Board under the symbol “ALLP.OB.”

NEITHER THE SECURITIES AND EXCHANGE COMMISSION NOR ANY STATE SECURITIES COMMISSION HAS APPROVED OR DISAPPROVED OF THESE SECURITIES OR PASSED UPON THE ACCURACY OR ADEQUACY OF THIS PROSPECTUS SUPPLEMENT. ANY REPRESENTATION TO THE CONTRARY IS A CRIMINAL OFFENSE.

The date of this Prospectus Supplement is September 8, 2005.

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of

The Securities Exchange Act of 1934

Date of Report (Date of earliest event reported) September 7, 2005

Alliance Pharmaceutical Corp.

(Exact name of registrant as specified in its charter)

New York	0-12950	14-1644018
(State or other jurisdiction	(Commission	(IRS Employer
of incorporation)	File Number)	Identification No.)

4660 La Jolla Village Drive, Suite 825	92122
(Address of principal executive offices)	(Zip Code)

Registrant’s telephone number, including area code (858) 410-5200

(Former name or former address, if changed since last report.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[_] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[_] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[_] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[_] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Item 1.01 Entry into a Material Definitive Agreement.

        On September 7, 2005, Alliance Pharmaceutical Corp. (“Alliance”) and/or its wholly-owned subsidiary Astral, Inc. (“Astral”) entered into the following definitive agreements related to the transfer of certain assets and the assumption of certain liabilities of Astral to and by Astral Therapeutics, Inc., a newly formed entity to be renamed MultiCell Immunotherapeutics, Inc. (“Transferee”): (i) Asset Contribution Agreement by and among Alliance, Astral, MultiCell Technologies, Inc. (“MultiCell”) and Transferee, (ii) Voting Agreement by and among Alliance, MultiCell and Transferee, (iii) Investor Rights Agreement by and among Alliance, MultiCell and Transferee, and (iv) IP Agreement and Release by and among MultiCell, Astral and Mixture Sciences, Inc.

        Pursuant to the Asset Contribution Agreement, Alliance and/or Astral has agreed to transfer to Transferee substantially all of the assets and business of Astral. The terms of the disposition of these assets are more fully described in Item 2.01 below. Pursuant to the Voting Agreement, the parties have agreed to vote their shares of Transferee capital stock so as to elect three directors of Transferee who shall initially be: (i) W. Gerald Newmin, MultiCell’s Chief Executive Officer, (ii) Stephen Chang, MultiCell’s President, and (iii) Duane Roth, Alliance’s Chief Executive Officer. Pursuant to the Investor Rights Agreement, each of Alliance and MultiCell has the right to maintain its respective pro rata ownership percentage in future financings of Transferee.

        In addition, Astral entered into an IP Agreement and Release (the “IP Agreement”) with Mixture Sciences, Inc. (“Mixture”) and MultiCell. Pursuant to the IP Agreement, Mixture assigned to Transferee certain intellectual property related to the Astral business previously assigned by Astral to Mixture. In consideration, MultiCell (i) paid $100,000 to Mixture, and (ii) issued to Mixture a warrant to purchase up to 400,000 shares of MultiCell’s common stock in satisfaction of all obligations and liabilities of Astral and/or Alliance to Mixture.

        A news release announcing the transaction is attached hereto as exhibit 99.1 to this Current Report on Form 8-K.

Item 2.01 Completion of Acquisition or Disposition of Assets.

        On September 7, 2005, Alliance and its wholly-owned subsidiary, Astral, transferred substantially all of the assets of Astral and the business of Astral, including, without limitation, the equipment and intellectual property rights primarily related to the business of Astral, to Transferee, a newly created entity formed solely for this purpose, in exchange for 490,000 shares of Transferee common stock (the “Asset Transfer”). In addition, Transferee assumed certain liabilities and/or obligations of Alliance and Astral related to the business of Astral. In connection with the Asset Transfer, MultiCell guaranteed the repayment and/or performance of the assumed liabilities and/or obligations by Transferee. In return, MultiCell received 510,000 shares of Transferee common stock.

        In addition, Transferee is obligated to sell and issue to MultiCell an additional 500,000 shares of Transferee’s Series A Preferred Stock for aggregate consideration of $2,000,000. After the sale and issuance of this Series A Preferred Stock to MultiCell is complete, Alliance will own approximately thirty-three percent (33%) of the outstanding capital stock of Transferee and MultiCell will own approximately sixty-seven percent (67%) of the outstanding capital stock of Transferee.

Item 9.01 Financial Statements and Exhibits.

(c) Exhibits

Exhibit No. Exhibit

2.1 Asset Contribution Agreement dated September 7, 2005 by and among Alliance Pharmaceutical Corp., MultiCell Technologies, Inc., Astral, Inc. and Astral Therapeutics, Inc.

99.1 News Release issued by Alliance Pharmaceutical Corp. on September 7, 2005.

SIGNATURES

        Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	ALLIANCE PHARMACEUTICAL CORP.
Date: September 8, 2005	/s/ Duane J. Roth
	Duane J. Roth, Chief Executive Officer

Exhibit 99.1

EX-99.1

ALLIANCE PHARMACEUTICAL CORP. ANNOUNCES THE TRANSFER OF
ASSETS OF ITS SUBSIDIARY ASTRAL, INC. TO A MULTICELL TECHNOLOGIES,
INC. SUBSIDIARY IN EXCHANGE FOR A FUNDING COMMITMENT AND
RETENTION OF EQUITY OWNERSHIP IN THE MULTICELL SUBSIDIARY

San Diego, CA; September 7, 2005 — Alliance Pharmaceutical Corp. (“Alliance”) and its wholly-owned subsidiary, Astral, Inc. (“Astral”) today announce that they have transferred substantially all of the assets of Astral and the business of Astral to Astral Therapeutics, Inc., a newly created entity formed solely for this purpose,  and to be re-named MultiCell Immunotherapeutics, Inc. (“MCTI”),  as set forth below. In return, Alliance will receive 490,000 shares of  MCTI common stock. In addition,  MCTI has assumed substantially all of the liabilities and/or obligations of Alliance and Astral related to the business of Astral, and MultiCell Technologies, Inc. (OTCBB: MCET) has guaranteed the repayment and/or performance of these liabilities and/or obligations  and will receive 510,000 shares of  MCTI common stock.

        Immediately after the closing of the asset transfer,  MCTI is also obligated to sell and issue to MultiCell an additional 500,000 shares of  MCTI’s  Series A Preferred Stock for an aggregate consideration of $2,000,000, to be paid $1,000,000 at the closing and the remaining $1,000,000 in four equal quarterly installments in the year after the closing, pursuant to a secured promissory note in favor of  MCTI. After the sale and issuance of the Series A Preferred Stock to MultiCell is complete, Alliance will own approximately thirty-three percent (33%) of the outstanding capital stock of  MCTI and MultiCell will own approximately sixty-seven percent (67%) of the outstanding capital stock of  MCTI. In addition, each of Alliance and MultiCell will have the right to maintain its respective pro rata ownership percentage in future financings of  MCTI. Immediately after the completion of the foregoing transactions, Astral Therapeutics, Inc. will change its name to MultiCell  Immunotherapeutics, Inc.

        Alliance Chairman and CEO, Duane Roth, commented “over the years we have invested in the basic research to prove the concepts behind this promising new immunotherapy. The agreement we reached with Multicell will provide the financial and human resources to advance this important technology towards the clinic.”

About Alliance

        Alliance Pharmaceutical Corp., founded in 1989, is a development-stage pharmaceutical company that is currently focused on developing its lead product, Oxygent^TM. Alliance is currently the only company that has advanced a synthetic PFC emulsion-based oxygen therapeutic into late-stage multi-center international clinical trials in both Europe and North America. Alliance is developing Oxygent^TM as an intravascular oxygen therapeutic, based on its proprietary PFC and surfactant technologies.

        Except for historical information, the matters set forth in this release are forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from those set forth herein, including the results of scientific advice of the regulatory authorities of the PRC and uncertainties associated with the conduct of preclinical or clinical studies. Alliance refers you to cautionary information contained in documents Alliance files with the Securities and Exchange Commission from time to time, including the last Form 10-KSB and Form 10-QSB, and those risk factors set forth in the most recent registration statement on Form SB-2 (File No. 333-119428). Alliance is under no obligation (and expressly disclaims any obligation) to update or alter its forward-looking statements, whether as a result of new information, future events, or otherwise.

Contact for further information in the U.S:
Corporate Communications
Alliance Pharmaceutical Corp.
San Diego, CA
(858) 410-5275